Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Accounts Payables (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Accounts Payables for 3 consecutive years, with $6.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables fell 45.25% to $6.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.8 million, a 45.25% decrease, with the full-year FY2024 number at $9.2 million, down 15.6% from a year prior.
  • Accounts Payables was $6.8 million for Q3 2025 at Inhibrx Biosciences, down from $8.3 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $13.0 million in Q2 2024 to a low of $6.8 million in Q3 2025.
  • A 3-year average of $9.9 million and a median of $9.2 million in 2024 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: dropped 15.6% in 2024, then crashed 45.25% in 2025.
  • Inhibrx Biosciences' Accounts Payables stood at $11.0 million in 2023, then decreased by 15.6% to $9.2 million in 2024, then dropped by 26.74% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Accounts Payables are $6.8 million (Q3 2025), $8.3 million (Q2 2025), and $8.9 million (Q1 2025).